Zebrafish Efficacy Testing

Real-Time Tumor Burden Quantification in a Living Vertebrate

Key Features:

• Patient-Derived & Cell-Line Xenografts --- Human tumor fragments or fluorescently labeled cell lines implanted into the perivitelline space; real-time tumor burden tracking via confocal fluorescence imaging.
• Angiogenesis & Microenvironment Analysis --- Vessel density quantification, immune cell infiltration tracking, and tumor-stroma interaction assessment using transgenic reporter lines.
• Combination Therapy Assessment --- Multi-drug regimen evaluation with synergy scoring and resistance mechanism profiling in the same animal.
• Ideal For --- Oncology lead validation; PDX-aligned personalized medicine programs; combination therapy prioritization; hit-to-lead transition.

Explore the Power of Screening-Ready Oncology Models:

For virtual biotechs with a single oncology asset, a zebrafish xenograft delivers quantitative tumor reduction data in 2--3 weeks---data you can present to your CSO and investors before committing to mouse efficacy studies. For pharma teams, our PDX-aligned models provide human-relevant tumor microenvironment data that cell-based assays cannot capture, with direct handoff to toxicity and ADMET teams for therapeutic window analysis.

In Vivo CNS Penetration and Phenotypic Rescue Validation

Key Features:

• Behavioral & Locomotor Rescue Assays --- Automated larval tracking (distance, velocity, thigmotaxis) under alternating light-dark cycles; standardized protocols for motor deficit quantification and drug-induced rescue.
• Neuronal Apoptosis & Angiogenesis Protection --- TUNEL staining, cerebrovascular density quantification, and neuroanatomical morphometrics using fluorescent reporters.
• Molecular Endpoint Validation --- Quantitative RT-PCR and western blot profiling of disease markers (caspase-3, BDNF, inflammatory cytokines) for mechanism-of-action confirmation.
• Ideal For --- Neurodegenerative target validation; CNS-penetrant compound screening; neuroprotective therapy assessment; NMR-based pharmacometabonomics correlation.

How It Works:

CNS drug development fails when compounds cannot penetrate the blood-brain barrier or rescue disease phenotypes in vivo. For biotechs developing neurodegenerative therapies, our locomotor rescue assays detect functional improvement at sub-lethal doses---signals that cell-based neuronal cultures miss entirely. For pharma teams, the behavioral and molecular endpoint data integrates directly with in vitro ADME-Tox profiling to build a CNS exposure-efficacy narrative for regulators.

In Vivo Cardiac Function Recovery and Cardioprotection

Key Features:

• Cardiac Ischemia-Reperfusion Models --- Pharmacologically induced cardiac injury with real-time monitoring of post-ischemic recovery; heart rate and ventricular function quantification.
• Cardioprotection Screening --- Evaluation of compounds for arrhythmia suppression, contractility restoration, and anti-apoptotic effects using cardiac troponin reporters.
• High-Resolution Functional Imaging --- Automated 96-well format confocal imaging with temperature-controlled stages for long-term cardiac observation and drug-response tracking.
• Ideal For --- Cardioprotection lead validation; anti-arrhythmic compound screening; cardiovascular regenerative therapy assessment; lead optimization stage cardiac efficacy follow-up.

Why It Matters:

Cardiovascular efficacy assessment requires whole-organism physiology where drug distribution, metabolism, and integrated cardiac function are intact. For biotechs developing cardioprotective agents, our ischemia-reperfusion models deliver quantifiable functional recovery data in 3--5 days---preserving runway while generating IND-relevant efficacy narratives. For pharma teams, the cardiac reporter data integrates directly with cardiotoxicity safety panels to establish the therapeutic window in the same model system.

Antimicrobial Efficacy and Immune Modulation in a Whole Organism

Key Features:

• Bacterial Infection Models --- Standardized bacterial burden assays (CFU quantification) with survival analysis and immune gene expression profiling.
• Vaccination & Prophylaxis Screening --- Immunization challenge models with antibody response correlation and pathogen clearance kinetics.
• Host-Pathogen Interaction Imaging --- Real-time tracking of bacterial dissemination and immune cell recruitment using transgenic fluorescent reporters.
• Ideal For --- Antimicrobial lead validation; vaccine adjuvant screening; host-directed therapy assessment; infectious disease hit identification stage de-risking.

What We Offer:

Infectious disease drug discovery demands whole-organism models where host immunity, pathogen virulence, and drug pharmacokinetics interact. Our bacterial infection models quantify pathogen clearance and survival rescue with statistical power, while RT-PCR immune profiling reveals whether efficacy is direct antimicrobial or host-modulatory. For virtual biotechs, this means mechanism-resolved efficacy data before Series A. For pharma teams, it means anti-infective leads with validated in vivo proof-of-concept and direct handoff to toxicity and lead optimization teams.